You remember that book, All I Really Need to Know I Learned in Kindergarten? Well, Pfizer
Yesterday, the media reported that Pfizer had received a warning letter from the Food and Drug Administration for not reporting adverse events in a timely manner.
After doctors report adverse events to the manufactures of the drugs patients are on, the FDA requires companies to pass along those reports to the agency within 15 days. According to media reports, the agency says Pfizer turned in adverse-event reports late about 13% of the time between March 2006 and July 2009 and even failed to turn in some reports all together.
There's no reason to think Pfizer's drugs are less safe than before. This seems to be more an issue with failing to follow directions than it is a giant conspiracy to cover up side effects. Shareholders seem to have shrugged off the reports, sending Pfizer higher with the rest of the market today.
Pfizer will eventually resolve this issue just like Boston Scientific
But investors need to watch the situation carefully to ensure it's not an epidemic; this has been going on for a while, after all. Stepping on the agency's toes a little too much can result in a consent decree, costing the company time and money, as Genzyme
C'mon, Pfizer. Get your act together and stop worrying your investors with stupid mistakes like this. We've got enough to worry about with getting drugs approved.
Jordan DiPietro explains how breaking rules can lead to killer returns.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is an Income Investor selection and Motley Fool Options recommended buying calls on the stock. The Fool has a disclosure policy.
More from The Motley Fool
Whom Will Pfizer Buy in 2018?
Keep your eyes on these three drugmakers.
3 Dividend Stocks With Better Yields Than PepsiCo
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.